Aileron Therapeutics Net Worth
Aileron Therapeutics Net Worth Breakdown | ALRN |
Aileron Therapeutics Net Worth Analysis
Aileron Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Aileron Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Aileron Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Aileron Therapeutics' net worth analysis. One common approach is to calculate Aileron Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Aileron Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Aileron Therapeutics' net worth. This approach calculates the present value of Aileron Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Aileron Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Aileron Therapeutics' net worth. This involves comparing Aileron Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Aileron Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Aileron Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Aileron Therapeutics' net worth research are outlined below:
| Aileron Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (15.73 M) with loss before overhead, payroll, taxes, and interest of (17.01 M). | |
| Aileron Therapeutics currently holds about 32.38 M in cash with (19.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36. | |
| Aileron Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Aileron Therapeutics Stock Surges Amid Positive Market Sentiment |
Aileron Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Aileron Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aileron Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Aileron Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aileron Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aileron Therapeutics backward and forwards among themselves. Aileron Therapeutics' institutional investor refers to the entity that pools money to purchase Aileron Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Royal Bank Of Canada | 2024-06-30 | 60.2 K | Warberg Asset Management Llc | 2024-06-30 | 31.4 K | Blackrock Inc | 2024-06-30 | 31.3 K | Blair William & Co | 2024-06-30 | 28 K | Texas Capital Bank Wealth Management Services Inc | 2024-06-30 | 26.2 K | Northern Trust Corp | 2024-09-30 | 25.8 K | Renaissance Technologies Corp | 2024-09-30 | 13.2 K | Kg&l Capital Management,llc | 2024-09-30 | 13 K | State Street Corp | 2024-06-30 | 10.4 K | University Of Texas Investment Mgmt Co | 2024-09-30 | 1.4 M | Alyeska Investment Group, L.p. | 2024-09-30 | 540 K |
Follow Aileron Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 59.36 M.Market Cap |
|
Project Aileron Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.77) | (0.81) | |
| Return On Capital Employed | (0.16) | (0.17) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (2.28) | (2.17) |
When accessing Aileron Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Aileron Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Aileron Therapeutics' profitability and make more informed investment decisions.
Evaluate Aileron Therapeutics' management efficiency
Aileron Therapeutics has return on total asset (ROA) of (0.2586) % which means that it has lost $0.2586 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4432) %, meaning that it created substantial loss on money invested by shareholders. Aileron Therapeutics' management efficiency ratios could be used to measure how well Aileron Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -0.81. In addition to that, Return On Capital Employed is likely to drop to -0.17. At this time, Aileron Therapeutics' Intangible Assets are very stable compared to the past year. As of the 29th of November 2024, Intangibles To Total Assets is likely to grow to 0.76, while Other Assets are likely to drop 0.00.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 21.37 | 20.31 | |
| Tangible Book Value Per Share | 2.78 | 2.64 | |
| Enterprise Value Over EBITDA | 0.21 | 0.22 | |
| Price Book Value Ratio | 2.04 | 2.14 | |
| Enterprise Value Multiple | 0.21 | 0.22 | |
| Price Fair Value | 2.04 | 2.14 | |
| Enterprise Value | -3.2 M | -3.1 M |
The strategic initiatives led by Aileron Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Return On Equity (0.44) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aileron Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aileron Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aileron Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aileron Therapeutics Corporate Filings
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 5th of November 2024 Other Reports | ViewVerify | |
F4 | 22nd of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 21st of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Aileron Therapeutics Earnings per Share Projection vs Actual
Already Invested in Aileron Therapeutics?
The danger of trading Aileron Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aileron Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aileron Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aileron Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aileron Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aileron Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aileron Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aileron Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aileron Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Return On Assets (0.26) | Return On Equity (0.44) |
The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aileron Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.